ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Sunday, November 7, 2021

8:30AM-10:30AM: Abstract Number: 0610

Evaluating Patient No Show Rates to Rheumatology Appointments Across a Regional Healthcare System

Healthcare Disparities in Rheumatology Poster (0594–0622)

8:30AM-10:30AM: Abstract Number: 0770

Evaluation of the Lupus Low Disease Activity State (LLDAS) vs. the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)-2K Score in a Pediatric Systemic Lupus Erythematosus Cohort

Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)

8:30AM-10:30AM: Abstract Number: 0859

Evaluation of the Montreal Cognitive Assessment as a Screening Tool for Cognitive Dysfunction in Systemic Lupus Erythematosus

SLE – Diagnosis, Manifestations, & Outcomes Poster II: Manifestations (0855–0896)

8:30AM-10:30AM: Abstract Number: 0908

Evaluation of the Nonsteroidal Anti-Inflammatory Drug-Sparing Effect of Secukinumab in Patients with Ankylosing Spondylitis: Multicenter, Randomised, Double-blind, Phase IV Study

Spondyloarthritis Including PsA – Treatment Poster I: Axial Spondyloarthritis (0908–0939)

8:30AM-10:30AM: Abstract Number: 0937

Evaluation of the Safety of Vedolizumab in Combination with Other Immunosuppression Biological Therapy in Patients with Inflammatory Bowel Disease

Spondyloarthritis Including PsA – Treatment Poster I: Axial Spondyloarthritis (0908–0939)

8:30AM-10:30AM: Abstract Number: 0782

Examining the Association of Socioenvironmental Factors with Depression and Anxiety Symptoms Among Youth with Childhood-Onset Systemic Lupus Erythematosus

Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)

8:30AM-10:30AM: Abstract Number: 0684

Extended Report: Successful Treatment anti-MDA5 Antibody-positive Interstitial Lung Disease with Plasma Exchange Therapy

Muscle Biology, Myositis & Myopathies Poster (0683–0722)

8:30AM-10:30AM: Abstract Number: 0514

Extracellular Sulfatase-2 Mediates TNF-α Inflammatory Signaling in Human Rheumatoid Arthritis Synovial Fibroblasts

Cytokines & Cell Trafficking Poster (0508–0516)

8:30AM-10:30AM: Abstract Number: 0936

Factors Associated with the Development of Anti-drug Antibodies to Tumour Necrosis Factor Inhibitors in Patients with Axial Spondyloarthritis; A Two Year Follow-up Study

Spondyloarthritis Including PsA – Treatment Poster I: Axial Spondyloarthritis (0908–0939)

8:30AM-10:30AM: Abstract Number: PP09

Family Planning while Living with Rheumatoid Arthritis

Patient Perspectives Poster (PP01–PP09)

8:30AM-10:30AM: Abstract Number: 0510

Fibrinogen Modified with Malondialdehyde-Acetaldehyde Adduct (MAA) And/or Citrulline (CIT) Induces Unique Cellular Responses in Human RA Synoviocytes

Cytokines & Cell Trafficking Poster (0508–0516)

8:30AM-10:30AM: Abstract Number: PP05

Fighting Health-Related Misinformation Using Social Media / How Creating an Online Group for Patients with Relapsing Polychondritis — and Moderating It with Health Professionals — Helps Spread Reliable and Empowering Information

Patient Perspectives Poster (PP01–PP09)

8:30AM-10:30AM: Abstract Number: 0928

Filgotinib Treatment Results in Reduction of Inflammatory and Matrix Remodeling Biomarkers Associated with Disease in Patients with Ankylosing Spondylitis

Spondyloarthritis Including PsA – Treatment Poster I: Axial Spondyloarthritis (0908–0939)

8:30AM-10:30AM: Abstract Number: 0836

Flare After Switching from Intravenous Tocilizumab to Subcutaneous Formulation in Patients with Rheumatoid Arthritis

RA – Treatments Poster I: Comparative Effectiveness, Biosimilars, Withdrawal, & the Real World (0813–0845)

8:30AM-10:30AM: Abstract Number: 0698

Flow Cytometry and Sorting of Single Antibody Secreting Cells from Frozen Muscle Tissue

Muscle Biology, Myositis & Myopathies Poster (0683–0722)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].